Clinical Trial Search

Primary: Mean Maximum Grade of Radiation Dermatitis by Treatment Arm. — 1.2; 1.3 Grade — p=0.18

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 37; 33; 34; 31 Participants

Primary: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 — 2.5724; 0.4611 percent predicted of FEV1 — p=0.1979

Primary: Change From Baseline in Influenza Virus Titer (48 Hours) — -1.66; -1.47 log10 TCID50/mL

Primary: Time to Alleviation of Symptoms (Kaplan-Meier Estimate) — 136.2; 114.1; 117.4 Hours — p=0.377

Primary: The Difference Between Achieved Flap Thickness at Day 1 Postoperative as Assessed by OCT and Expected Flap Thickness as Determined Pre-operatively — 14.996; 13.644 microns

Primary: Methamphetamine Dependent Subjects Treated With Citicoline vs Placebo — 0.3025; 0.3850 total amount consumed in grams

Primary: Acute Stress Measured by Tension — 3089.4; 3253.4 mm*min — p=0.1233

Primary: Progression-Free Survival (PFS) - Percentage of Participants With an Event — 92.3 percentage of participants

Primary: Percentage of Participants Who Died Assessed From Point of Randomization — 81.3; 85.7 percentage of participants

Primary: Quality of Life: SF-12 Physical Component Summary (PCS) — 36.9; 41.2; 45.6; 44.6 scores on a scale

Primary: Acute Stress Measured by Tension — 3335.7; 3360.3 mm*min — p=0.7726

Primary: Feasibility-response Rate — 46; 51 % of Soldiers returning mailed survey

Primary: Percentage of Participants With PD According to Response Evaluation Criteria in Solid Tumors (RECIST) or Death (Data Cutoff 17 May 2008) — 89.5; 79.9 percentage of…

Primary: Number of Participants With Treatment-Related Adverse Events (AEs) — 0 Participants